$HUMA
Humacyte Inc. (NASDAQ: HUMA) is trading at approximately $2.48 per share. The stock opened at $2.56, with a daily range between $2.46 and $2.62. Over the past month, HUMA has experienced a significant increase of over 70%, although it remains down approximately 66% over the past year.
Recent Developments
Symvess™ Commercial Launch: Humacyte initiated the commercial launch of Symvess™, its bioengineered vascular tissue product, achieving first-quarter sales of $147,000. Total revenue for Q1 2025 was $517,000, including $370,000 from a research collaboration.
FDA Approval: In December 2024, the FDA approved Symvess™ for the treatment of extremity vascular trauma, marking a significant milestone for the company.
Financial Measures: To support the commercialization of Symvess™, Humacyte raised $50 million through a public offering in March 2025, pricing 25 million shares at $2.00 each.
Operational Adjustments: In an effort to conserve cash, Humacyte announced job cuts affecting approximately 31 employees, representing about 12% of its workforce.
Analyst Ratings
Benchmark: Maintained a "Buy" rating with a price target of $17.00.
HC Wainwright & Co.: Assigned a "Buy" rating with a price target of $4.00.
These ratings suggest optimism about Humacyte's growth potential, particularly with the commercial rollout of Symvess™.
